强直性脊柱炎的市场份额、大小的趋势,Industry Analysis Report, By Drug (Cosentyx, Humira, Simponi, Remicade, Enbrel, Cimzia, Others); By Treatment Type (Painkillers and NSAIDs, DMARDs, Biological Therapies, Steroids, Physical Therapies, Surgery); By Regions; Segment Forecast, 2021 - 2028

报告摘要

The global ankylosing spondylitis (AS) market was valued at USD 4.48 billion in 2020 and is expected to grow at a CAGR of 8.5% during 2021-2028. Factors fueling the market growth include a strong drug pipeline, the presence of off-label drugs, rising cases of ankylosing spondylitis, and concerning investments in the sector.

了解有关此报告的更多信息：request for sample pages

强直性脊柱炎是一种炎症性关节炎，以不同的方式影响不同人物的脊柱，主要是与其他相关问题。尽管存在缺乏对个人的意识，但情况并不罕见，并影响英国约220,000人。肌肉骨骼疾病对NHS的经济负担约6至9％的人，代表医疗实践的人，以某种方式与背部疼痛有关，超过10％仅显示强直性脊柱炎的特征。

Industry Dynamics

Growth Drivers
Approval and commercialization of novel drugs and consequently increasing collaborations between the companies are expected to accelerate the market growth. For instance, in August 2020, AbbVie announced to apply to its drug candidate RINVOQ (upadacitinib; 15 mg), to the USFDA, for the treatment of people, actively suffering from ankylosing spondylitis.

该公司还向欧洲药物局（EMA）提交申请，为患有强直性脊柱炎的患者，过去必须接受常规疗法。对FDA和EMA的申请得到了来自Select-Axis 1的市场数据，涉及药物候选的II / III研究表明阳性症状。该研究揭示了52％以上的人们会见了主要终点，具有一致的安全性。

2019年8月，Eli Lilly收到其药物，Taltz注射液80 mg / ml的批准，用于治疗强直性脊柱炎的活跃病例。该产品已经批准用于银屑病关节炎，并在2016年和2017年中度至重度斑块性牛皮癣。

Moreover, in September 2018, Gilead Lifesciences and Galapagos N.V. co-developed, Filgotinib, which already has completed phase II clinical trials for treating patients with moderate to severe ankylosing spondylitis. Moreover, the patent cliff has led to the flooding of a biosimilar in the market to improve patient access and outcome.

强直性脊柱炎市场报告范围

该市场主要是在药物，治疗类型和地理区域的基础上进行分割：

通过药物	By Treatment Type	按地区
cosentyx. Humira Simponi. Remicade Enbrel Cimzia. Others	止痛药和非甾体类抗炎药（NSAID） 疾病改性抗风湿药物（DMARDS） Biological therapies Steroids Physical therapies 手术	北美（美国，加拿大） 欧洲（法国，德国，英国，意大利，西班牙，荷兰，奥地利） Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea) 拉丁美洲（巴西，墨西哥，阿根廷） 中东和非洲（沙特阿拉伯，阿联酋，以色列，南非）

了解有关此报告的更多信息：request for sample pages

药物洞察力

基于药物，强直性脊柱炎市场分为COSTENTYX，HUMIRA，SIMPONI，REMICADE，ENBREL，CIMZIA等。2020年，杜拉强直性脊柱膜炎产业段占股份最大，由于其高效性和低成本。相反，由于在所选地区的生物纤维单模的专利到期和强烈的竞争，预计该产品预计将期望销售额下降。

然而，预计Costentyx强直性脊柱膜炎产业部门将在预测期内注册最高的市场增长。2019年10月，诺华获得了欧洲医学的批准，用于非射线照相轴向脊髓灰质炎的COSENTENTX。该公司计划向FDA提交标签更新申请，曾经受到EM批准的。

Geographic Overview

地理位置上，该市场被隔离为北美，亚太地区，欧洲，南美洲和中东和非洲。北美强直性脊柱炎市场是欧洲和亚太市场最大的区域收入贡献者。大多数公司在市场上运营的强直性脊柱炎，虽然没有FDA批准的药物，但这些公司正在投资很多，以获得首先提高第一款的优势和产品排他性。

For instance, in August 2019, researchers at the Spondylitis Association of America in support of the National Institute of Arthritis and Musculoskeletal and Skin Diseases found two new genes ARTS1 and IL23R responsible for spondylitis. IL23R is largely plays role in an individual’s immune system during infection, while ARTS1 is cutting down infectious foreign agents into pieces.

除了HLA-B27，这两个新的基因可以帮助医生识别风险，患有强调脊柱炎的风险，可能导致疾病的免疫处理。这些调查结果使科学界密切了解强大的脊柱炎，并帮助反驳了强直性脊柱炎是一种自身免疫性疾病。

Moreover, rising drug approvals in emerging countries such as India and China are contributing to the region’s growth. For instance, in September 2020, China-based biopharma company Innovent Biologics Inc. announced the approval of Sulinno (adalimumab injection), an anti-TNF monoclonal antibody-drug by the Chinese regulator National Medical Products Administration (NMPA) for the treatment of the AS, including psoriasis and rheumatoid arthritis.

竞争洞察力

The prominent players operating in ankylosing spondylitis market are AbbVie, Inc., Pfizer, Inc., Novartis AG, Amgen, Inc., Johnson & Johnson Services, Inc., Eli Lilly and Company, UCB, Inc., and Merck & Co., Inc. The companies in the market for ankylosing spondylitis are strongly focusing on research and development efforts of various pharmaceutical companies to have better option of treatment. For instance, Pfizer announced to recruit clients for its clinical study and remission criterion of its drug candidate etanercept.